Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

15 Jul 2011

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Epigenetics and DNA Methylation
Share to Myeloproliferative Neoplasms: Diagnosis and Treatment

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 21760590
DOI: 10.1038/leu.2011.170

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-AzacytidinePMID 21760590Read ↗

TET2 mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemiaSemantic proximity Read ↗

TET2 mutations in myelodysplasia and myeloid malignancies.Semantic proximity Read ↗

Significance of JAK2 and TET2 mutations in myelodysplastic syndromes.Semantic proximity Read ↗

[Molecular and clinical characteristics and prognosis of myelodysplastic neoplasms with biallelic TET2 inactivation].Semantic proximity Read ↗

Role of DNA Methylation in the Pathogenesis and Treatment of Myelodysplastic SyndromesSemantic proximity Read ↗

Life after hypomethylating agents in myelodysplastic syndrome: new strategies.Semantic proximity Read ↗

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromesSemantic proximity Read ↗

ID4 methylation predicts high risk of leukemic transformation in patients with myelodysplastic syndromeSemantic proximity Read ↗

Mutations of ASXL1 and TET2 in aplastic anemiaSemantic proximity Read ↗

Current status of epigenetic treatment in myelodysplastic syndromesSemantic proximity Read ↗

Epigenetic Function of TET Family, 5-Methylcytosine, and 5-Hydroxymethylcytosine in Hematologic MalignanciesSemantic proximity Read ↗

Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.